FAAH

Fatty acid amide hydrolase

FAAH (Fatty acid amide hydrolase) is an integral membrane enzyme that degrades the fatty acid amide family of signaling lipids, including the endocannabinoid anandamide. Genetic or pharmacological inactivation of FAAH leads to analgesic, anti-inflammatory, anxiolytic, and antidepressant phenotypes in rodents without showing the undesirable side effects observed with direct cannabinoid receptor agonists, indicating that FAAH may represent an attractive therapeutic target for treatment of pain, inflammation, and other central nervous system disorders.

FAAH Inhibitors

1-Monomyristin

Cat. No.: HY-N2512

1-Monomyristin, extracted from Serenoa repens, inhibits the hydrolysis of 2-oleoylglycerol (IC_{50}=32 μM) and fatty acid amide hydrolase (FAAH) activity (IC_{50}=18 μM).



Purity: >98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Acetylhydrolase-IN-1

Cat. No.: HY-102054

Acetylhydrolase-IN-1 is a 1-Alkyl-2-acetylglycerophosphocholine esterase (**Alkylacetyl-GPC: acetylhydrolase**) inhibtor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BIA 10-2474

Cat. No.: HY-19740

BIA 10-2474 is an inhibitor of fatty acid amide hydrolase (**FAAH**) with IC_{50} values of 50 to 70mg/kg in various rat brain regions.



Purity: 98.41%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Biochanin A

(4-Methylgenistein; Olmelin)

Cat. No.: HY-14595

Biochanin A is a naturally occurring fatty acid amide hydrolase (**FAAH**) inhibitor, which inhibits FAAH with IC_{50}s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.



Purity: 98.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 200 mg, 500 mg

Carprofen

Cat. No.: HY-B1227

Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target **FAAH/COX** inhibitor, with IC_{50}s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

FAAH inhibitor 1

(Benzothiazole analog 3)

Cat. No.: HY-10862

FAAH inhibitor 1 (Benzothiazole analog 3) is a potent **fatty acid amide hydrolase (FAAH)** inhibitor with an IC_{50} of 18±8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FAAH-IN-1

Cat. No.: HY-111389

FAAH-IN-1 is a fatty acid amide hydrolase (**FAAH**) inhibitor, with IC_{50}s of 145 nM and 650 nM for rat and human FAAH, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FAAH-IN-2

(O-Desmorpholinopropyl Gefitinib)

Cat. No.: HY-79511

FAAH-IN-2 (O-Desmorpholinopropyl Gefitinib) is a potent FAAH(fatty acid amide hydrolase) inhibitor extracted from Patent WO/2008/100977A2.



Purity: 96.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 500 mg, 1 g, 5 g

JNJ-1661010

(Takeda-25)

Cat. No.: HY-N7062

JNJ-1661010 (Takeda-25) a potent and selective **fatty acid amide hydrolase (FAAH)** inhibitor with IC_{50}s of 34 and 33 nM for rat FAAH and human FAAH, respectively. JNJ-1661010 can cross the blood-brain barrier and used as broad-spectrum analgesics.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JNJ-42165279

Cat. No.: HY-19636

JNJ-42165279 is a FAAH inhibitor with IC50 of 70 ± 8 nM and 313 ± 28 nM for hFAAH and rFAAH, respectively.



Purity: 99.97%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

JZL195

Cat. No.: HY-15250

JZL195 is a selective and efficacious dual **fatty acid amide hydrolase (FAAH)** and **monoacylglycerol lipase (MAGL)** inhibitor with IC_{50}s of 2 and 4 nM, respectively.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LY2183240

Cat. No.: HY-10865

LY2183240 is a novel and highly potent blocker of anandamide uptake (IC50 = 270 pM). LY2183240 inhibits fatty acid amide hydrolase (FAAH) activity (IC50 = 12.4 nM). IC50: 270 pM (anandamide uptake); 12.4 nM (FAAH) Target: FAAH; Anandamide uptake Following i.p.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

N-(3-Methoxybenzyl)Palmitamide

Cat. No.: HY-N2428

N-(3-Methoxybenzyl)Palmitamide is a promising inhibitor of **FAAH** for the treatment of pain, inflammation and CNS degenerative disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

N-Benzyloleamide

Cat. No.: HY-N6923

N-Benzyloleamide is a maccamide isolated from Lepidium meyenii (Maca). N-Benzyloleamide irreversibly inhibits fatty acid amide hydrolase **(FAAH)**. N-benzyloleamide influences the energy metabolism and reveals antioxidant and antifatigue activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

N-Benzylpalmitamide

(N-Benzylhexadecanamide; Macamide 1)

Cat. No.: HY-N2365

N-Benzylpalmitamide is a macamide isolated from Lepidium meyenii, acts as an inhibitor of **fatty acid amide hydrolase (FAAH)**.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 1 mg

N-Benzyllinolenamide

Cat. No.: HY-N3033

N-Benzyllinolenamide is a natural macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (**FAAH**) with an IC_{50} of 41.8 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

PF 750

Cat. No.: HY-18081

PF 750 is a selective and covalent **fatty acid amide hydrolase (FAAH)** inhibitor, with IC_{50}s varied from 16.2-595 nM in different pre-incubation times. Covalently modifies the enzyme's active site serine nucleophile.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 5 mg

PF-04457845

Cat. No.: HY-14376

PF-04457845 is a highly efficacious and selective **FAAH** inhibitor with IC_{50} values is 7.2±0.63 nM and 7.4±0.62 nM for **h**FAAH and **r**FAAH, respectively.



Purity: 99.37%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-3845

Cat. No.: HY-14380

PF-3845 is a selective fatty acid amide hydrolase (FAAH) inhibitor (Ki = 0.23 μM); showing negligible activity against FAAH2. IC50 value: 0.23 uM Target: FAAH PF-3845 selectively inhibits FAAH by carbamylating FAAH's serine nucleophile . PF-3845 treated mice (10 mg/kg, i.p.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SA 47

Cat. No.: HY-18080

SA 47 is a selective and potent inhibitor of **fatty acid amide hydrolase (FAAH)** and **carbamate**.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

SA57

Cat. No.: HY-103463

SA57 is a potent, selective **FAAH** inhibitor with **IC_{50}**s of 3.2 nM and 1.9 nM for **mouse and human FAAH**.



Purity: >99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SA72

Cat. No.: HY-U00240

SA72 is a highly selective **fatty acid amide hydrolase (FAAH)** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

URB-597

(KDS-4103)

Cat. No.: HY-10864

URB597 is a potent, orally bioavailable FAAH inhibitor with IC50 of 4.6 nM, with no activity on other cannabinoid-related targets.



Purity: 99.01%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg